Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 204
States / cities: Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions: Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist, GVAX; Radiation · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peripheral Arterial Disease, Diabetic Foot, Diabetes Mellitus
Interventions: ABI/WIFI scoring; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions: Continuous Glucose Monitoring with treatment algorithm; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina

Conditions: Pleuropulmonary Blastoma, Cystic Nephroma, Sertoli-Leydig Cell Tumor of Ovary, Medulloepithelioma, Embryonal Rhabdomyosarcoma of Cervix, Goiter, Sarcoma, Pineoblastoma, Pituitary Tumors, Wilms Tumor
Interventions: Not listed
Lead sponsor: Ashley Hill; Other
Eligibility: 1 Day to 95 Years
Enrollment: 1,247 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: Quotient Diagnostics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Escondido, California • Chaska, Minnesota • Columbia, Missouri

Conditions: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Chronic Kidney Diseases, Healthy Lifestyle
Interventions: Individualized basic need navigation and lifestyle coaching and skills training, Enhanced usual care; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Male Hypogonadism
Interventions: Testosterone; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 30
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 26 more

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: 6 Years to 18 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Vitamin D Deficiency, Secondary Hyperparathyroidism, Obesity
Interventions: Ergocalciferol, Cholecalciferol; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Liraglutide, Saline; Drug
Lead sponsor: Ildiko Lingvay; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 51
States / cities: Peoria, Arizona • Artesia, California • Concord, California + 48 more

Conditions: Diabetes
Interventions: Sitagliptin, Metformin, Sitagliptin + Metformin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetic Foot Ulcer, Osteomyelitis Chronic
Interventions: Borate-base Bioactive Glass Fiber Matrix (BBGFM); Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin, pioglitazone; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 318 participants
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Achondroplasia
Interventions: BMN 111; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 6 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 11
States / cities: Oakland, California • Torrance, California • Wilmington, Delaware + 8 more

Conditions: Hypogonadism
Interventions: GnRH antagonist (Acyline); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis; Biological · Genetic · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus in Obese
Interventions: Aerobic exercise training; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Wound, Burn Wound, Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, Chronic, Wound
Interventions: Epiceram Skin Barrier Function, Vaseline Petroleum Jelly; Device · Biological
Lead sponsor: Sashwati Roy; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2034
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Cincinnati; Other
Eligibility: 19 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
Interventions: Aveed Injectable Product, Fortesta, Testim; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Brivekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more

Conditions: Type 1 Diabetes
Interventions: FMPD AP algorithm, MPC AP system, Dexcom G6 Continuous Glucose Monitoring (CGM) System; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Implementation of ABI and WIfI in Rural Health Clinics

Examining The Role of CGM in T2DM

Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome

Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System

Basic Needs Navigation Intervention to Address Multidimensional Adversity in African Americans With Diabetic Kidney Disease

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

Microalbuminuria in Children With and Without Diabetes

Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM

Mirragen Diabetic Foot Ulcer Study

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Heart Rate Variability-Guided Exercise Training in Type 2 Diabetes

Wound Healing Endpoint and Recurrence

Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

Two Way Crossover Closed Loop Study MPC vs FMPD